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Abstract
A male patient, born to unrelated Belgian parents, presented at 4 months with epistaxis,
haematemesis and haematochezia. On physical examination he presented petechiae and
haematomas, and a slightly enlarged liver. Serum transaminases were elevated to 5-10 times upper
limit of normal, alkaline phosphatases were 1685 U/L (<720), total bilirubin was 2.53 mg/dl (<1.0),
ammonaemia 69 μM (<32), prothrombin time less than 10%, thromboplastin time >180 s (<60) and
alpha-fetoprotein 29723 μg/L (<186). Plasma tyrosine (651 μM) and methionine (1032 μM) were
strongly increased. In urine, tyrosine metabolites and 4-oxo-6-hydroxyheptanoic acid were
increased, but succinylacetone and succinylacetoacetate - pathognomonic for tyrosinemia type I -
were repeatedly undetectable. Delta-aminolevulinic acid was normal, which is consistent with the
absence of succinylacetone. Abdominal ultrasound and brain CT were normal.
Fumarylacetoacetase (FAH) protein and activity in cultured fibroblasts and liver tissue were
decreased but not absent. 4-hydroxyphenylpyruvate dioxygenase activity in liver was normal, which
is atypical for tyrosinemia type I. A novel mutation was found in the FAH gene: c.103G>A
(Ala35Thr). In vitro expression studies showed this mutation results in a strongly decreased FAH
protein expression.
Dietary treatment with phenylalanine and tyrosine restriction was initiated at 4 months, leading to
complete clinical and biochemical normalisation. The patient, currently aged 12 years, shows a
normal physical and psychomotor development.
This is the first report of mild tyrosinemia type I disease caused by an Ala35Thr mutation in the
FAH gene, presenting atypically without increase of the diagnostically important toxic metabolites
succinylacetone and succinylacetoacetate.
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Introduction
Type I tyrosinemia (OMIM +276700), also called hepato-
renal tryosinosis, is a severe inborn metabolic disease
affecting the tyrosine degradation pathway. It often
presents with liver disease or liver failure with predomi-
nant bleeding tendency, Fanconi syndrome and/or rickets
(for a comprehensive review, see [1]). Type I tyrosinemia
is caused by a mutation in the gene encoding for the
fumarylacetoacetate hydrolase or fumarylacetoacetase
(FAH) enzyme, an enzyme in the tyrosine degradation
pathway. Deficiency of this enzyme causes intracellular
accumulation of fumarylacetoacetate (FAA), a tyrosine-
derived metabolite upstream of the deficient FAH
enzyme. FAA is thought to be genotoxic and therefore car-
cinogenic. Intracellular FAA is rapidly degraded to succi-
nylacetone (SA) and succinylacetoacetate (SAA), which
are also thought to be carcinogenic. Patients with type I
tyrosinemia can also develop acute neuropathic pains or
polyneuropathy with respiratory failure, reminiscent of
acute porphyria, due to inhibition of heme-synthesis at
the level of aminolevulinic acid dehydratase, by the pro-
duced toxic metabolites of tyrosine degradation [1].
The diagnosis of type I tyrosinemia is based on the pres-
ence of liver disease, kidney disease and/or rickets,
increased tyrosine and methionine in plasma and the
presence of SA in urine and blood and SAA in urine. In
addition to SA and SAA, the presence of 4-oxo-6-hydroxy-
heptanoic acid in urine has also been described as pathog-
nomonic [2]. The presence of SA and SAA is considered
pathognomonic for the disease. Up till now, no type I
tyrosinemias without SA or SAA in urine have been
described [1]. The diagnosis of type I tyrosinemia is con-
firmed by measurement of FAH enzyme activity in cul-
tured fibroblasts (or on liver tissue) and/or detection of
disease-causing mutations in the FAH gene. In total, 44
FAH mutations are listed in the Human Genome Muta-
tion database http://www.hgmd.cf.ac.uk.
Type I tyrosinemia is treated with a protein-restricted diet,
amino acid supplements low in tyrosine, phenylalanine
and methionine, and nitisinone. Nitisinone is a drug that
inhibits 4-hydroxyphenylpyruvate dioxygenase, an
enzyme upstream of FAH, thereby preventing the forma-
tion of the toxic compounds FAA, SA and SAA [1]. Typi-
cally, the activity of this enzyme is already reduced in type
I tyrosinemia, presumably be feedback-inhibition of the
accumulating toxic end-products in the diseased patient.
The natural history of the typical disease is an evolution to
liver failure, cirrhosis with hepatocellular carcinoma, end-
stage renal failure, acute neuropathic pains and hyper-
trophic cardiomyopathy.
The evolution of the disease has improved considerably
since the introduction of nitisinone treatment, but -
depending on the age at diagnosis and start of treatment -
development of liver and kidney disease is not entirely
excluded. Especially the occurrence of hepatocellular car-
cinoma is a dreaded complication.
Materials and methods
Isolation of RNA and Northern blotting
The isolation of total RNA from fibroblasts, electrophore-
sis, blotting and hybridisation with a 32P-labelled single
stranded FAH probe, was performed as described previ-
ously [3]. The membranes were reprobed with pig β-actin
cDNA as control.
Western blotting
Was performed according to Berger et al. [4].
Genomic PCR, sequencing and restriction analysis
A genomic DNA product of 252 bp across FAH exon 2 was
PCR amplified with primers 5'-GGACTCTTCAATA-
GACAGG-3' (sense, intron 1) and 5'-CCACAGTAAGT-
GCCACTGAG-3' (antisense, intron 2) and used for direct
sequencing (Thermo Sequenase radiolabeled terminator
cycle sequencing kit from Amersham, The Netherlands).
For enzyme restriction analysis a 175 bp PCR product
across the mutation was amplified by 30 cycles of 94°C
for 30 sec and 60°C for 60 sec, followed by 3 min final
extension at 72°C. The primers were 5'-ATCTTCCTC-
CTAGCCAAGACCGAGGATAGGGGTG-3' (sense) and 5'-
CCACAGTAAGTGCCACTGAG-3' (antisense). A mis-
match (underlined) in the sense primer together with the
Ala35Thr mutation creates a restriction site for Bst EII. The
PCR assay contained, in a total volume of 100 μl, 5-10 μl
of cell lysate, 10 μl of PCR buffer, 0.2 mM of each dNTP,
40 pmol of each primer, 2 μmol MgCl2 and 1 μl
Dynazyme DNA polymerase. The PCR products were
digested with either HaeIII or Bst EII and electrophoresed
on 3.5% NuSieve minigels. With HaeIII the 175 bp PCR
product without mutation is digested into fragments of
142 and 33 bp. With Bst EII the product with the Ala35Thr
mutation is digested into fragments of 141 and 34 bp.
Mutagenesis and expression analysis
Mutagenesis using the Altered Sites In Vitro Mutagenesis
System (Promega), expression analysis using TnT Cou-
pled Reticulocyte Lysate System (Promega), determina-
tion of FAH activity of the translated products, and
autoradiography of 35S-methionine-labeled translation
products subjected to PAGE were performed as previously
described [3].Orphanet Journal of Rare Diseases 2009, 4:28 http://www.ojrd.com/content/4/1/28
Page 3 of 6
(page number not for citation purposes)
Liver enzyme activities and urinary and blood organic acid 
analysis
Were performed as described previously [2,5].
Case Description
A 4 month old boy, born at 37 weeks of gestation, to non-
consanguineous Caucasian parents presented at the emer-
gency department with epistaxis, hematemesis and hema-
tochezia. He was born following a pregnancy complicated
with maternal oedema and preterm contractions. On
physical exam at 4 months, petechiae, a subconjunctival
bleeding in the left eye and a friable haemangioma on the
inside of the left cheek were noted. The liver was slightly
enlarged. Serum transaminases were elevated to 5-10
times upper limit of normal, alkaline phosphatase was
1685 U/L (<720), total bilirubin was 2.53 mg/dl (<1.0),
ammonaemia was 69 μM (<32), prothrombin time was
less than 10% (>70), thromboplastin time was >180 s
(<60) and alpha-fetoprotein was 29723 μg/L (<186).
Hepatitis caused by drugs, hepatitis viruses or hepato-
tropic viruses was excluded.
Plasma tyrosine (651 μM) and methionine (1032 μM)
were strongly increased. In urine, tyrosine metabolites
and 4-oxo-6-hydroxyheptanoic acid were increased, but
SA and SAA were repeatedly undetectable. Delta-aminole-
vulinic acid was normal, which is consistent with the
absence of SA. There was no tubulopathy, skeletal X-ray
showed no rickets. Abdominal ultrasound and brain CT
were normal.
Treatment with restriction of natural protein and amino
acid formula low in phenylalanine and tyrosine was initi-
ated at 4 months. Nitisinone was initially not started
because of absence of the supposedly toxic metabolites of
tyrosinemia type I and complete clinical and biochemical
normalisation on diet (normal liver tests, alpha-fetopro-
tein, coagulation tests).
Fumarylacetoacetase (FAH) mRNA in fibroblasts was nor-
mal (Fig. 1). FAH protein and activity in cultured fibrob-
lasts (Fig. 1) and liver tissue (Table 1) were decreased but
not absent. 4-hydroxyphenylpyruvate dioxygenase activ-
ity in liver was normal, which is atypical for tyrosinemia
type I. A novel mutation was found in the FAH gene:
c.103G>A (Ala35Thr). (Fig. 2) Homozygosity for this
mutation in the patient, heterozygosity in both his par-
ents, was shown by restriction analysis with HAEIII and
BstEII. (Fig. 3) In vitro expression studies showed this
mutation resulted in absence of FAH protein expression.
(Fig. 4)
Because of clinical and biochemical normalisation (table
2 and 3), the diet was terminated at the age of 22 months.
Parameters remained normal during follow-up. At the age
of 6 years the diet was reintroduced together with nitisi-
none treatment (0.5 mg/kg, later increased to 1.0 mg/kg)
after the identification of a hypointense lesion on MRI of
the liver. The lesion was considered suspicious and was
resected. Pathological examination showed a region of
disturbed microcirculation, no arguments for malignancy.
Electron microscopy of the tissue surrounding the
resected lesion showed enlarged mitochondria with
paracrystalline inclusions together with hypertrophy of
the Golgi apparatus. These findings are non-specific, but
suggestive of toxicity. Annual follow-up liver MRI up till
now (12 years of age) has shown no focal lesions. The
patient's psychomotor development is normal. His renal
function is normal. He is still on diet and nitisinone ther-
apy.
Discussion
We report here a case of a mild Type I Tyrosinemia, pre-
senting typically with liver disease (jaundice, bleeding
tendency), increased tyrosine and methionine in plasma,
but absence of the pathognomonic markers SA and SAA
from urine. The diagnosis of type I tyrosinemia is sup-
ported by the demonstration of 4-oxo-6-hydroxyhepta-
noic acid in urine, a strongly decreased but measurable
Expression of fumarylacetoacetase (FAH) mRNA and protein  in fibroblast extracts Figure 1
Expression of fumarylacetoacetase (FAH) mRNA 
and protein in fibroblast extracts. A: Northern blot (1). 
Patient mRNA in lane 2 and 4, control sample in lane 1 and 3. 
Upper panel: probed with a 32P-labeled FAH cDNA. Lower 
panel: reprobed with pig beta-actin. B: Western blot (2). 
Patient protein in lane 2, control samples in lanes 1, 3 and 4. 
FAH mRNA is expressed in the patient's fibroblasts, but FAH 
protein could not be detected.Orphanet Journal of Rare Diseases 2009, 4:28 http://www.ojrd.com/content/4/1/28
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FAH enzyme activity in liver tissue and fibroblasts and the
demonstration of a novel mutation in the FAH gene
(Ala35Thr). In the first 6 years following diagnosis, the
condition was successfully managed with a tyrosine/
methionine-restricted diet, resulting in rapid and com-
plete resolution of liver disease.
Identification of the Ala35Thr mutation Figure 2
Identification of the Ala35Thr mutation. PCR-amplified 
genomic DNA was sequenced and revealed a G to A transi-
tion in the first nucleotide of codon 35 in exon 2 of the FAH 
gene, leading to a substitution of Ala by Thr.
The Ala35Thr mutation can be confirmed by restriction anal- ysis Figure 3
The Ala35Thr mutation can be confirmed by restric-
tion analysis. Lanes 1 and 5: control. Lanes 2 and 6: the 
patient's mother. Lanes 3 and 7: the patient's father. Lanes 4 
and 8: the patient. Restriction analysis with HAEIII and BstEII, 
on DNA extracted from blood, confirms heterozygosity for 
the Ala35Thr mutation in both parents and homozygosity in 
the patient.
Expression analysis of Ala35Thr mutated FAH Figure 4
Expression analysis of Ala35Thr mutated FAH. Using 
the TnT Coupled Reticulocyte Lysate System (Promega) (2), 
wild-type FAH and mutated FAH were expressed. An auto-
radiography of 35S-methionine-labeled translation products 
separated by polyacrylamide gel electrophoresis is shown. 
Lanes 1 and 7: luciferase expression (control). Lanes 2 and 6: 
expression of 43 kDa FAH control. Lane 3: expression of 
FAH mutant with Ala35Thr. Lane 4: plasmid without insert. 
Lane 5: no DNA control. Ala35Thr mutation of the FAH 
gene leads to absence of protein expression.
Table 1: Liver enzyme activities
Biopsy I Biopsy II Tyr type III Controls
FAH 2.2 1.8 33 41 (38.8-46.4)
4-HPD 11 8.7 0.2 15 (10.8-18.4)
ASAT 3472 2669 2490 1731,1641
ALAT 700 810 1340 665, 1034
LDH 3315 2223 3420 3755, 3045
Column 1 shows the result of a first biopsy in the presented patient 
(at diagnosis), the second column of a confirmatory biopsy in the 
same patient. Column 3 shows the results in a type III tyrosinemia, for 
comparison. The last column shows control values. FAH is clearly 
decreased, but measurable in both biopsies in our patient (approx. 5% 
of normal). 4-HPD is unexpectedly not equally decreased as would be 
expected in type I tyrosinemia, also contrasting with the value 
measured in the type III tyrosinemia biopsy. The fact that 4-HPD is 
not decreased, is compatible with the absence of SA and SAA in our 
patient. ASAT, ALAT and LDH are internal controls, demonstrating 
the quality of the tissue samples used.
FAH: fumarylacetoacetate hydrolase; 4-HPD: 4-
hydroxyphenylpyruvate dioxygenase; ASAT: aspartate transaminase; 
ALAT: alanine transaminase; LDH: lactate dehydrogenaseOrphanet Journal of Rare Diseases 2009, 4:28 http://www.ojrd.com/content/4/1/28
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Although apparently mild in presentation, we do not con-
sider it likely that the disease only became clinically
apparent, by the presence of an intercurrent problem, e.g.
a viral or xenobiotic-induced hepatitis, since the most
likely causes of hepatitis were excluded in this patient, by
standard hepatitis work-up. The cause of the hepatitis epi-
sode in this patient, with a striking coagulopathy and
highly increased α-fetoprotein typical of Type I Tyrosine-
mia, was therefore most likely the suggested mild type I
tyrosinemia.
In type I tyrosinemia patients with a cirrhotic liver, liver
nodules demonstrating a reversion to the normal FAH
genotype and showing normal FAH enzyme activity have
been described [5]. The reversion is thought to result from
a combination of mutation pressure exerted by the toxic
compounds produced in these patients (FAA, SA, SAA),
combined with a high rate of liver cell proliferation. In the
patient reported here, there was no advanced liver disease
or generalised nodular transformation at the time of
biopsy, so the measured residual FAH enzyme activity is
considered a genuine residual activity (of about 5%). In
the transgenic lethal albino mice, 0.3%-4.3% of normal
expression of FAH was shown to be compatible with a
normal life-span of the mice [6], which is concordant with
the described evolution of our patient so far.
In our opinion, the normal SA and SAA in this patient is
due to the residual activity of the FAH enzyme. The
absence of the typical suppression of both the aminole-
vulinic acid dehydratase and 4-hydroxyphenylpyruvate
dioxygenase, supports the observation that SA and SAA
are low. Inversely, absence of suppression of these
enzymes in the presence of type I tyrosinemia, supports
Table 2: Urinary organic acid analysis results
Age 4 months 5 months 8 months 18 months
Succinylacetone 0.2 0.1 0.1 ≈ 0.1
Succinylacetoacetate ≈ 0.1 <0.1 ≈ 0.3 <0.1
4 - o x o - 6 - h y d r o x y h e p t a n o i c  a c i d 4128
creatinine, mmol/L 3.1 1.6 3.1 3.2
A significantly increased excretion of aberrant tyrosine metabolites was detected, with 4-oxo-6-hydroxyheptanoic acid as the dominant metabolite. 
The excretion of phenolic tyrosine metabolites was not significantly increased: in the first sample 4-hydroxyphenylpyruvate was 7 mmol/mol 
creatinine, which can be considered as marginally increased (ref value in newborns <10, in infants <5). In later samples, we found 4-
hydroxyphenylpyruvate <1 mmol/mol creatinine (reference value <5) and 4-hydroxyphenyllactate 2 mmol/mol creatinine (reference value < 10). 
These values are in accordance with a normal 4-hydroxyphenylpyruvate dioxygenase activity (Table 1).
Table 3: Blood and urine biochemistry and enzymatic activities
Age 4
months
5
months
8
months
18
months
30
months
6 years
Start NTBC
6 years and
1 month
Unit Ref range
BLOOD
PBG synthase in 
RBC
nkat/g Hb 0.58-1.25 -- 0.51 0.17 0.05 0.06 0.11 0.870
Succinylacetone in 
plasma
μmol/L < 0.1 0.88 0.13 <0.1 0.33 0.38 0.27 <0.10
α-Fetoprotein in 
serum
μg/L <12 -- 28000 50 11 <5 <5 <5
Tyrosine in plasma μmol/L 50-130 693 36 73 96 112 130 381
Phenylalanine in 
plasma
μmol/L 40-120 196 57 72 70 83 89 45
Methionine in plasma μmol/L 20-50 1300 400 30 20 39 34 15
URINE
5-Aminolevulinic 
acid
mmol/mol 
creatinine
0-3 6.9 5.3 8.8 25 17 7.9 3.5
Succinylacetone mmol/mol 
creatinine
<1 <1 <1 <1 <1 1.1 0.3 <0.1
Succinylacetoacetate mmol/mol 
creatinine
<1 <1 <1 <1 <1 <1 <0.3 <0.1
4-oxo-6-
hydroxyheptanoic 
acid
mmol/mol 
creatinine
< 1 412 84 . 2 6 < 0 . 1
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the supposition that it is indeed these compounds that
normally suppress their activity in typical type I tyrosine-
mia.
In view of the complete resolution of liver disease in this
patient under dietary restrictions, and absence of the
metabolites considered toxic in this disease, no nitisinone
treatment was started. The evolution over the first 6 years
of life was entirely uneventful. Nitisinone was started
from 6 years to date (current age 12 years), because of a
cancer scare (identification and resection of a suspicious
liver lesion that proved not malignant). In addition, the
lack of hard data on the absence of evolution to end-stage
liver disease with hepatocellular carcinoma, or to tubu-
lopathy in this hitherto undescribed type I tyrosinemia
inspired prudency in the treating physicians.
Finally, since there apparently can be tyrosinemia presen-
tations without SA in urine and without increased ami-
nolevulinic acid, this has to be taken into account in the
interpretation of those newborn screening programs, test-
ing for SA [7] or aminolevulinic acid [8] in urine. The
patient presented here would not have been detected by
such screening program and nevertheless has proven type
I tyrosinemia.
In conclusion, we present a patient homozygous for a pre-
viously undescribed mutation in the FAH gene
(Ala35Thr), leading to a mild type I tyrosinemia and
probably amenable with diet. This mild tyrosinemia pre-
sented without urinary SA and SAA.
List of abbreviations
FAA: fumarylacetoacetate; FAH: fumarylacetoacetate
hydrolase or fumarylacetoacetase; SA: succinylacetone;
SAA: succinylacetoacetate.
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